信必可联合噻托溴铵吸入剂治疗重症哮喘的临床分析.docxVIP

信必可联合卩塞托漠彼吸入剂治疗重症哮喘的临床分析 汪建明 四川省简阳市中医医院四川简阳641400 【摘 要】目的：探讨重症哮喘患者应用信必可联合曝托漠鞍吸入剂治疗的 临床效果。方法：选取重症哮喘患者进行分析，随机分为两个不同组别。其中一 组釆用常规治疗方案，另一组采用信必可联合卩塞托澳钱吸入治疗方案。观察两组 患者的临床治疗效果，以及不良反应情况。结果：试验组治疗有效率(94.1%) 明显高于对照组(73.5%),患者治疗后的PEF、FEV1、6MWT指标均优于对照组。 PV0.05,差异有统计学意义。试验组不良反应发生率为8.8%,对照组为5.9%, 差异不具有统计学意义(P0.05)o结论：在重症哮喘患者中，应用信必可联合 曝托澳镀吸入治疗效果更佳，能够改善肺功能指标，且不良反应少，是一种安全 有效的治疗方案。 【关键词】重症哮喘；信必可；嗟托澳鞍；临床效果；不良反应 【中图分类号】R256.12 【文献标识码】B 【文章编号】1764-8999 (2015) 7-0469-02 Letter will can be joint thiamethoxam bromide inhalant clinical analysis for the treatment of severe asthma Wang Jian ming Sichuan jianyang 641400 sichuan jianyang TCM hospital [Abstract[Objective: to study the application letter must be severe asthma joint thiamethoxam Joe bromide in halation therapy of clin ical effect. An alysis methods: selecting patients with severe asthma, were randomly divided into two different groups. One group of the conventional treatment, another set of the letter will can joint thiamethoxam bromide in haled treatme nt. Observe the clin ical therapeutic effect of two groups of patients, and adverse reactions. Results: the experimental group treatment efficient (94.1%) is significantly higher than control group (73.5%), patients after treatment of PEF, FEV1, 6 MWT indicators are better than the control group. P lt; 0.05, the differenee was statistically significant. Group the incidenee of adverse reactions was 8.8%, control group was 5.9%, no statistically sign汗icant difference (P gt; 0.05). Conclusion: in patients with severe asthma, application letter must be joint thiamethoxam bromide in haled treatme nt effect is better, it can improve lung function index, and less adverse reaction, is a kind of safe and effective treatme nt. 【Key words］ severe asthma; Letter must be; Thiamethoxam Joe bromide; Clinical effect; Adverse reactions 作为常见的肺部疾病，重症哮喘主要特征是气流受限，导致患者出现呼吸困 难，降低了患者的运动能力和生活质量。有研究显示，随着我国老龄化社会的到 来和环境污染的加剧，该疾病发病率呈现持续上升趋势［1］。为了探究药物治疗 的临床效果，本文选取我院收治的患者进行分析，结果如下： 1资料与方法 1.1 一般资料 选取我院收治的重症哮喘患者68例